Talipexole and adult Gilles de la tourette's syndrome: Double‐blind, placebo‐controlled clinical trial
- 1 January 1994
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 9 (3) , 315-317
- https://doi.org/10.1002/mds.870090306
Abstract
Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double‐blind, placebocontrolled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.Keywords
This publication has 10 references indexed in Scilit:
- D-2 dopamine autoreceptor selective drugs: Do they really exist?Life Sciences, 1990
- Chronic Treatment with Talipexole Dihydrochloride on Abnormal Involuntary Movement in HumansClinical Neuropharmacology, 1990
- A rating scale for Gilles de la Tourette's syndromeNeurology, 1987
- The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of catsEuropean Journal of Pharmacology, 1987
- Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methodsAnnals of Neurology, 1987
- Clonidine Benefits Children with Attention Deficit Disorder and Hyperactivity: Report of a Double-Blind Placebo-Crossover Therapeutic TrialJournal of the American Academy of Child Psychiatry, 1985
- CSF Cholinesterase Activity in Gilles de la Tourette's SyndromeArchives of Neurology, 1984
- Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndromeNeurology, 1984
- Effects of B‐HT 920 and B‐HT 933 on Dopamine and Noradrenaline Autoreceptors in the Rat BrainActa Pharmacologica et Toxicologica, 1983
- Haloperidol-Induced Tardive Dyskinesia in a Child With Gilles de la Tourette's DiseaseArchives of Neurology, 1980